Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4, Single-Arm, Open-Label Trial to Evaluate the Safety and Efficacy of Veligrotug in Participants With Thyroid Eye Disease (TED) Who Previously Responded to Teprotumumab

NCT07832136 is registered in ClinicalTrials.gov with Viridian Therapeutics, Inc. as lead sponsor.

NCT NCT07832136
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07832136 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4, Single-Arm, Open-Label Trial to Evaluate the Safety and Efficacy of Veligrotug in Participants With Thyroid Eye Disease (TED) Who Previously Responded to Teprotumumab
Lead sponsor
Viridian Therapeutics, Inc.
Phase
Phase 4
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
September 30, 2027
Enrollment
30 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

thyroid eye disease